60 patents
Page 3 of 3
Utility
Methods for Detecting Neutralizing Antibodies to Parathyroid Hormone (PTH) and Parathyroid Hormone-related Peptide (PTHRP) Analog
16 Dec 21
The present disclosure is directed to methods (e.g., in vitro methods) for detecting the presence of neutralizing antibodies to PTH or PTHrP analog in a sample.
Heidi K. Chandler
Filed: 7 Jul 21
Utility
Transdermal System for the Delivery of Abaloparatide and Method of Use for Treating Osteoporosis
9 Dec 21
Provided herein are methods for treating osteoporosis and increasing bone mass density, that includes administering once a day, for about 5 minutes, a transdermal patch loaded with about 300 μg of abaloparatide, and ZnCl2 at a molar ratio of 2.2:1 of ZnCl2:abaloparatide.
Kenneth Brown, Ehab Hamed, Alan Harris, Gary Hattersley, Joan Moseman, Jamal Saeh, Lisa Dick
Filed: 6 Aug 21
Utility
Formulations of Abaloparatide, Transdermal Patches Thereof, and Uses Thereof
2 Dec 21
Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
Filed: 23 Mar 21
Utility
Methods for Treating Cancer Resistant to CDK4/6 Inhibitors
28 Oct 21
Disclosed herein are methods of treating a CDK4/6 inhibitor resistant estrogen receptor alpha-positive cancer in a subject having either a wild-type estrogen receptor alpha and/or a mutant estrogen receptor alpha, the method comprising administering to the subject a therapeutically effective amount of elacestrant, or a pharmaceutically acceptable salt or solvate thereof, wherein the mutant estrogen receptor alpha comprises one or more mutations selected from the group consisting of D538G, Y537X1, L536X2, P535H, V534E, S463P, V392I, E380Q and combinations thereof, wherein: X1 is S, N, or C; and X2 is R or Q.
Hitisha PATEL, Teeru BIHANI, Heike ARLT, Nianjun TAO
Filed: 6 Dec 19
Utility
Stable Cannabinoid Formulations
28 Oct 21
The present invention is generally directed to substantially pure cannabidiol, stable cannabinoid pharmaceutical formulations, and methods of their use.
Kiran Kumar Vangara, Huaguang Li, Ningxin Yan, Hung Q. Nguyen, Venkat R. Goskonda
Filed: 6 Jul 21
Utility
Polymorphic forms of RAD1901-2HCL
19 Oct 21
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 6 Jul 20
Utility
Polymorphic Forms of RAD1901-2HCL
2 Sep 21
Various polymorphic forms of RAD1901-2HCl, including four crystalline and amorphous forms, are prepared and characterized.
Michael Paul CRUSKIE, Joshua Kyle BOLGER, Jonathan Blake MCKENZIE, Pratik SHETH, Richard EDWARDS, Alex EBERLIN, Michael MARKEY
Filed: 3 Jul 19
Utility
Abaloparatide formulations and methods of testing, storing, modifying, and using same
4 May 21
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 28 Aug 19
Utility
METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
25 Feb 21
The present invention provides compositions, devices, methods and processes related to the intradermal delivery of PTHrP and PTHrP analogues, particularly [Glu22,25, Leu23,28,31, Aib29, Lys26,30]hPTHrP(1-34)NH2.
Gary Hattersley, Kris J. Hansen, Amy S. Determan, Ying Zhang
Filed: 31 Aug 20
Utility
USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
2 Dec 20
Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures.
Gary Hattersley
Filed: 15 Jun 20
Utility
Methods for Treating Cancer
25 Nov 20
Fiona GARNER, Gary HATTERSLEY
Filed: 3 Aug 20
Utility
Polymorphic Forms of RAD1901-2HCL
18 Nov 20
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, JR., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 5 Jul 20
Utility
Estrogen Receptor-modulating Compounds
4 Nov 20
Described herein are compounds that are estrogen receptor modulators.
Chris Miller
Filed: 21 Jan 19
Utility
Polymorphic forms of RAD1901-2HCl
17 Aug 20
Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized.
Michael Paul Cruskie, Jr., Joshua Kyle Bolger, Jonathan Blake McKenzie, Pratik Sheth, Richard Edwards, Alex Eberlin, Michael Markey
Filed: 12 Sep 19
Utility
Ar+ Breast Cancer Treatment Methods
3 Jun 20
A method for treating AR+ breast cancer in a subject comprising administering to the subject an AR agonist (e.g., SARMs such as RAD140), or in combination with one or more therapeutic agents selected from the group consisting of cdk4/6 inhibitors, m-TOR inhibitors, PI3k inhibitors, PARP inhibitors, BCL-2 inhibitors, and MCL-1 inhibitors.
Gary Hattersley, Jamal Saeh, Ziyang Yu, Chris Miller, Teeru Bihani
Filed: 25 Nov 19
Utility
Formulations of Abaloparatide, Transdermal Patches Thereof, and Uses Thereof
27 May 20
Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
Filed: 2 Jan 20
Utility
USES OF PTHrP ANALOGUE IN REDUCING FRACTURE RISK
26 Feb 20
Disclosed herein are PTHrP or analogues thereof, such as abaloparatide, for preventing or reducing bone fractures in subjects in need thereof, as well as methods of using PTHrP or analogues thereof to prevent or reduce bone fractures.
Gary Hattersley
Filed: 9 Sep 19
Utility
Formulations of abaloparatide, transdermal patches thereof, and uses thereof
24 Feb 20
Disclosed are abaloparatide formulations for transdermal delivery of a therapeutically effective amount of abaloparatide, as well as transdermal patches prepared using these formulations, methods of preparing the disclosed formulations and patches, and methods of using these formulations and patches to treat osteoporosis, osteopenia, osteoarthritis, and/or bone fracture, improve bone mineral density (BMD), improve trabecular bone score (TBS), and treat, prevent, and/or reduce bone fractures.
Gary Hattersley, Alan Harris, Jamal Saeh, Ehab Hamed, Kenneth Brown, Daniel Dohmeier, Joan Moseman, Ying Zhang, Lisa Dick
Filed: 5 Apr 17
Utility
Abaloparatide Formulations and Methods of Testing, Storing, Modifying, and Using Same
19 Feb 20
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers.
Greg Williams, Naveen Palwai, David Hanley
Filed: 27 Aug 19
Utility
Methods For Treating Ovarian Cancer
8 Jan 20
Methods of treating ovarian cancer are disclosed.
Gary Hattersley
Filed: 26 Sep 17